FISPB
VRDN icon

Fideuram - Intesa Sanpaolo Private Banking’s Viridian Therapeutics VRDN Stock Holding History

Fideuram - Intesa Sanpaolo Private Banking’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.69M Buy
92,148
+22,618
+33% +$364K 0.05% 245
2026
Q1 		$1.36M Buy
69,530
+6,801
+11% +$202K 0.05% 260
2025
Q4 		$1.95M Buy
+62,729
New +$1.72M 0.07% 222

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Fideuram - Intesa Sanpaolo Private Banking's VRDN Position: Q2 2026 in Review

Fideuram - Intesa Sanpaolo Private Banking increased its Viridian Therapeutics (VRDN) stake by 33% in Q2 2026, buying an estimated $364K and bringing the position to 92,148 shares worth $1.69M. The position accounts for 0.05% of the portfolio, ranked #245.

Fideuram - Intesa Sanpaolo Private Banking first reported a position in VRDN in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.95M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Fideuram - Intesa Sanpaolo Private Banking held 92,148 shares of Viridian Therapeutics worth $1.69M as of Q2 2026.
  • Fideuram - Intesa Sanpaolo Private Banking bought 22,618 Viridian Therapeutics shares in Q2 2026, an estimated $364K.
  • Viridian Therapeutics made up 0.05% of Fideuram - Intesa Sanpaolo Private Banking's portfolio in Q2 2026, its #245 holding.
  • Fideuram - Intesa Sanpaolo Private Banking first reported a position in Viridian Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Fideuram - Intesa Sanpaolo Private Banking's Viridian Therapeutics position peaked at $1.95M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Fideuram - Intesa Sanpaolo Private Banking's 13F filing for Q2 2026, filed 23 Jul 2026.